Last reviewed · How we verify
Argimate (ARGININE GLUTAMATE)
Argimate (generic name: ARGININE GLUTAMATE) is a arginine glutamate drug. It is currently in Phase 3 development.
Arginate works by increasing the production of nitric oxide, a molecule that helps to relax blood vessels and improve blood flow.
Arginate is a small molecule. It is also known by the synonyms Arginine Glutamate.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ARGININE GLUTAMATE |
|---|---|
| Drug class | arginine glutamate |
| Target | Nitric oxide synthase, inducible |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Think of nitric oxide like a message that tells blood vessels to relax and let more blood flow through. When this message is sent, blood vessels widen, and blood pressure decreases. This can be helpful for people with conditions like high blood pressure or heart disease.
Approved indications
Common side effects
Key clinical trials
- pH1N1 Blinded Challenge Study (PHASE1)
- A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PHASE2)
- L-arginine Supplementation and Exercise; L-arginine Supplementation and Renal Function (PHASE4)
- Neurotransmitter Levels in Children With Specific Learning Disorder (NA)
- Daily Amino Acid Supplementation for People With Parkinson's Disease (NA)
- Prandial Metabolic Phenotype in Adults (NA)
- Metabolic Processes in Adults and Adolescents With Autism Spectrum Disorder (NA)
- Chronic Obstructive Pulmonary Disorder and Acute Exercise (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Argimate CI brief — competitive landscape report
- Argimate updates RSS · CI watch RSS
Frequently asked questions about Argimate
What is Argimate?
How does Argimate work?
What is the generic name of Argimate?
What drug class is Argimate in?
What development phase is Argimate in?
What does Argimate target?
Related
- Drug class: All arginine glutamate drugs
- Target: All drugs targeting Nitric oxide synthase, inducible
- Therapeutic area: All drugs in Cardiovascular
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing